Review article: How to control and improve adherence to therapy in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 3, 2006, Pages 45-49

  Lopez Sanroman A ^a   Bermejo, F ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BILIRUBIN; CYCLOSPORIN A; SALICYLIC ACID; TACROLIMUS;

CHRONIC DISEASE; DEMOGRAPHY; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG MONITORING; ENTERITIS; ERYTHROCYTE METABOLISM; FOLLOW UP; HUMAN; MEAN CORPUSCULAR VOLUME; MEDICAL LITERATURE; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT INFORMATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; URINALYSIS;

HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 33748328055     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03060.x     Document Type: Review

References (24)

1. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185-91.
2. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
3. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333-6.
4. Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 69-73.
5. Lopez San Roman A, Bermejo F, Carrera E, Perez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 249-57.
6. Bernal I, Marín L, Garcia-Planella E, et al. Cumplimiento terapéutico y automediación en una cohorte de pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2005; 28: 145.
7. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44.
8. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with non adherence to statin therapy. Pharmacotherapy 2005; 25: 1035-43.
9. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43.
10. Farup PG, Hovde O, Halvorsen FA, Raknerud N, Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995; 30: 164-70.
11. Eaden J. Review article: The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl. 2): 15-21.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
13. Shaw IS, Jobson BA, Silverman D, et al. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. Aliment Pharmacol Ther 2002; 16: 2053-9.
14. Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 161-6.
15. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-3.
16. Robinson A. Review article: Inflammatory bowel disease - empowering the patient and improving outcome. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 84-7.
17. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1470-9.
18. Maunder RG, Lancee WJ, Hunter JJ, Greenberg GR, Steinhart AH. Attachment insecurity moderates the relationship between disease activity and depressive symptoms in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 919-26.
19. Maunder R, Toner B, de Rooy E, Moskovitz D. Influence of sex and disease on illness-related concerns in inflammatory bowel disease. Can J Gastroenterol 1999; 13: 728-32.
20. Martin A, Leone L, Castagliuolo I, Di Mario F, Naccarato R. What do patients want to know about their inflammatory bowel disease? Ital J Gastroenterol 1992; 24: 477-80.
21. Maunder R, Esplen MJ. Facilitating adjustment to inflammatory bowel disease: a model of psychosocial intervention in non-psychiatric patients. Psychother Psychosom 1999; 68: 230-40.
22. Odes HS. 5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis. J Clin Gastroenterol 1997; 24: 287-8.
23. Cawdron R, Issenman RM. Patient web-resource interest and Internet readiness in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35: 518-21.
24. Panes J, de Lacy AM, Sans M, Soriano A, Pique JM. Elevado índice de consultas por Internet de los pacientes catalanes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2001; 25: 306-9.